Endogenous opioids acting at a medullary μ-opioid receptor contribute to the behavioral antinociception produced by GABA antagonism in the midbrain periaqueductal gray

• Published in: Neuroscience 1996-10, Vol.74 (3), p.863-872
• Main Authors: Roychowdhury, S.M., Fields, H.L.
• Format: Article
• Language: English
• Subjects: Animals; bicuculline; Bicuculline - administration & dosage; Bicuculline - pharmacology; Biological and medical sciences; Brain Mapping; CTOP; Fundamental and applied biological sciences. Psychology; GABA Antagonists - pharmacology; Male; Medulla Oblongata - drug effects; Medulla Oblongata - physiology; Mesencephalon - drug effects; Mesencephalon - physiology; Microinjections; Models, Neurological; naloxone; Naloxone - administration & dosage; Naloxone - pharmacology; naltrexone; Naltrexone - pharmacology; Narcotic Antagonists - pharmacology; Pain; Periaqueductal Gray - drug effects; Periaqueductal Gray - physiology; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu - physiology; rostroventromedial medulla; Somatostatin - analogs & derivatives; Somatostatin - pharmacology; Somesthesis and somesthetic pathways (proprioception, exteroception, nociception); interoception; electrolocation. Sensory receptors; Spinal Cord - physiology; Time Factors; Vertebrates: nervous system and sense organs
• ISSN: 0306-4522; 1873-7544
• DOI: 10.1016/0306-4522(96)00180-7

This study examined the contribution of endogenous opioids to the antinociception produced by microinjection of the GABA A receptor antagonist, bicuculline, into the rat midbrain ventrolateral periaqueductal gray region. Microinjection of bicuculline (40 ng/0.4 μl) into the periaqueductal gray produced robust antinociception as measured by the tail-flick latency to noxious heat. This antinociception was partially reversed by intravenous administration of the non-selective opioid antagonist naloxone hydrochloride (1 and 5 mg/kg), indicating that endogenous opioid release is necessary for this effect. To determine whether opioid release in the rostral ventromedial medulla, a major projection target of the periaqueductal gray, contributes to this effect, we microinjected another opioid antagonist, naltrexone, into the rostral ventromedial medulla. Naltrexone in the rostral ventromedial medulla (5 and 10 μg/μl) significantly attenuated bicuculline antinociception elicited from the periaqueductal gray. Cys 2,tyr 3,orn 5,pen 7-amide (26.5 nmol), a selective μ-opioid receptor antagonist, also reversed the antinociception when microinjected into the rostral ventromedial medulla. Microinjections of naltrexone (10 μg/μl) or cys 2,tyr 3,orn 5,pen 7-amide at sites in the medulla dorsal to the rostral ventromedial medulla were ineffective. None of the antagonists altered baseline tail-flick latencies. These results support the hypothesis that a population of periaqueductal gray neurons produces antinociception through a μ-opioid receptor-mediated action of endogenous opioids in the rostral ventromedial medulla. Thus, two opioid-sensitive pain-modulating brainstem sites are linked by an endogenous opioid synapse in the rostral ventromedial medulla.